AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04038684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Weight Control (MBWC)
Description: Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
Study NCT04038684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Control (SBWC)
Description: Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
Study NCT04600128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dairy-based greek yogurt
Description: Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
Study NCT04600128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dairy-based cheddar cheese
Description: Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
Study NCT04600128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based yogurt
Description: Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
Study NCT04600128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based cheese
Description: Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
Study NCT04427566 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
Study NCT00496808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin (Trastuzumab)
Description: 8 mg/kg IV Over 90 Minutes
Study NCT01721655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
Study NCT01119144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycaprolactone / Tri-Calcium Phosphate
Description: Orbital implant for reconstruction of the orbital walls
Study NCT01119144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Mesh
Description: Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
Study NCT01721655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
Study NCT01256801 — intervention group
Intervention type: BIOLOGICAL
Intervention: cytokine
Description: interleukin 2 2 million unit every week
Study NCT00345839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Study NCT02117752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Study NCT02117752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium lauryl sulfate
Description: Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
Study NCT02117752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patches containing normal saline (Negative Control) will be applied to the skin.
Study NCT02652689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diagnostic ultrasound radiation
Description: Recording Doppler ultrasound signals from the right chest wall
Study NCT04541303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: tranexamic acid diluted to concentration of 25ml/mg
Study NCT04541303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.9% sodium chloride
Study NCT00798642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: 8 weeks of gut-directed hypnotherapy
Study NCT00798642 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: 8 weeks of standard of care
Study NCT00798642 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mind Body Therapy
Description: 8 weeks of mind-body therapy
Study NCT03282526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body plethysmography
Description: Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
Study NCT00805922 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Capillary or venous blood will be drawn for analysing HbA1c.
Study NCT02165345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants >/= 30 kg: once weekly
Study NCT03412500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin equation-based method
Description: Vancomycin dosage will be adjusted according to the equation-based method
Study NCT03412500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin trough concentration method
Description: Vancomycin dosage will be adjusted according to the trough concentration method
Study NCT00901381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 µg/kg subcutaneously once daily x 5 days
Study NCT01664819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant
Study NCT01664819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02320630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entanercept
Description: Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
Study NCT03230799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery
Description: ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
Study NCT02327117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02327117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01816919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collecting breath samples
Study NCT02320630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
Study NCT02000661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
Study NCT02000661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
Study NCT01345175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
Study NCT01345175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
Study NCT01992224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mechanical Ventilation
Description: Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation
Study NCT01992224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Mechanical Ventilation
Description: other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
Study NCT03584815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery/Fasciotomy
Description: Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
Study NCT03584815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
Study NCT00608049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate and low glycemic index (GI) diet
Description: The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
Study NCT02320630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
Study NCT03838003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERIC protocol
Description: ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
Study NCT01576406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg twice a day
Study NCT01576406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250 mg once a day
Study NCT00608049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and low GI diet
Description: The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
Study NCT00608049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate and high GI diet
Description: The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
Study NCT00608049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate and high GI diet
Description: The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
Study NCT03573245 — intervention group
Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Tranexamic acid effect on perioperative bleeding in orthopedic surgery
Study NCT02393339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Pre-operative administration of Paracetamol syrup
Study NCT02393339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pre-operative administration of placebo syrup
Study NCT02186756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback and Usual care
Description: Please refer to arm description
Study NCT00771212 — intervention group
Intervention type: OTHER
Intervention: Observational pain control study
Description: Observational pain control study
Study NCT01907607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day.
Study NCT03282526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Whole body plethysmography
Description: Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
Study NCT00589277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed counseling & Gain-framed materials
Description: Novel messages for quitting smoking
Study NCT00589277 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care counseling + standard materials
Description: Standard messages for quitting smoking
Study NCT02292498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR ONE
Study NCT01267604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH (rFSH)
Description: 225IU
Study NCT01267604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rFSH + Inositol + Melatonin
Description: 225IU rFSH, 4g Inositol, 3mg Melatonin
Study NCT00364819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
Study NCT04939870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical parameters evaluation
Description: selected biochemical parameters
Study NCT02288182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann VivOss
Description: Patients will receive Straumann VivOss for sinus augmentation.
Study NCT02288182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss
Description: Patients will receive Geistlich Bio-Oss for sinus augmentation.
Study NCT02381951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation (St Jude Medical)
Description: implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
Study NCT01055132 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lens
Description: contact lens to correct astigmatism
Study NCT01055132 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lens
Description: contact lens to correct astigmatism
Study NCT06032962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingectomy
Description: surgical removal of the fallopian tubes
Study NCT01159197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
Study NCT01342536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)
Description: The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)
Study NCT01342536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)
Description: The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)
Study NCT01395641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gene therapy
Description: AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
Study NCT02218970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Study NCT03549117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Right Tan (small/medium) nasal strips
Description: Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
Study NCT03549117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal strip
Description: Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
Study NCT03148756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
Study NCT03148756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
Study NCT00696436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.
Study NCT00696436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.